Addition of pioglitazone to RA therapy improves insulin resistance and modestly reduces RA disease activity measured by DAS28-CRP and two of its components, patient-reported GH and CRP, but not DAS28-ESR or ESR. This evidence concerns the gene CRP and Insulin resistance.